Background: Adult-onset Still's disease (AOSD),a rare autoinflammatory disorder, resembles systemic juvenile idiopathic arthritis (SJIA). The superimposable systemic clinical features of AOSD and SJIA suggest both clinical phenotypes represent the same disease continuum with different ages of onset. To further characterize the similarity between AOSD and SJIA at the molecular level, 2 previously identified response gene sets in SJIA were used to investigate how genes that respond to interleukin (IL)-1 beta inhibition with canakinumab in SJIA patients behave in AOSD patients with active disease prior to IL-1 beta targeting therapy, relative to healthy subjects. Findings: All genes downregulated in SJIA patients following canakinumab treatmen...
Background: Canakinumab is a human anti-interleukin-1β (IL-1β) monoclonal antibody neutralizing IL-1...
Background: Canakinumab is a human anti-interleukin-1\u3b2 (IL-1\u3b2) monoclonal antibody neutraliz...
Background: Canakinumab is a human anti-interleukin-1β (IL-1β) monoclonal antibody neutralizing IL-1...
Background: Adult-onset Still's disease (AOSD),a rare autoinflammatory disorder, resembles systemic ...
Background: Adult-onset Still's disease (AOSD),a rare autoinflammatory disorder, resembles systemic ...
Background: Adult-onset Still's disease (AOSD),a rare autoinflammatory disorder, resembles systemic ...
Background: Adult-onset Still's disease (AOSD),a rare autoinflammatory disorder, resembles systemic ...
Background: Adult-onset Still’s disease (AOSD), a rare autoinflammatory disorder, resembles systemic...
Background: Adult-onset Still's disease (AOSD), a rare autoinflammatory disorder, resembles systemic...
Background: Canakinumab is a human anti-interleukin-1 beta (IL-1 beta) monoclonal antibody neutraliz...
13301甲第4507号博士(医学)金沢大学博士論文本文Full 以下に掲載:Clinical Immunology 169 pp.8-13 2016. Elsevier. 共著者:Natsumi I...
OBJECTIVES: Juvenile idiopathic arthritis (JIA) is a heterogeneous group of conditions unified by th...
BACKGROUND: Canakinumab is a human anti-interleukin-1β (IL-1β) monoclonal antibody neutralizing IL-1...
BACKGROUND: Canakinumab is a human anti-interleukin-1β (IL-1β) monoclonal antibody neutralizing IL-1...
Background: Canakinumab is a human anti-interleukin-1β (IL-1β) monoclonal antibody neutralizing IL-1...
Background: Canakinumab is a human anti-interleukin-1β (IL-1β) monoclonal antibody neutralizing IL-1...
Background: Canakinumab is a human anti-interleukin-1\u3b2 (IL-1\u3b2) monoclonal antibody neutraliz...
Background: Canakinumab is a human anti-interleukin-1β (IL-1β) monoclonal antibody neutralizing IL-1...
Background: Adult-onset Still's disease (AOSD),a rare autoinflammatory disorder, resembles systemic ...
Background: Adult-onset Still's disease (AOSD),a rare autoinflammatory disorder, resembles systemic ...
Background: Adult-onset Still's disease (AOSD),a rare autoinflammatory disorder, resembles systemic ...
Background: Adult-onset Still's disease (AOSD),a rare autoinflammatory disorder, resembles systemic ...
Background: Adult-onset Still’s disease (AOSD), a rare autoinflammatory disorder, resembles systemic...
Background: Adult-onset Still's disease (AOSD), a rare autoinflammatory disorder, resembles systemic...
Background: Canakinumab is a human anti-interleukin-1 beta (IL-1 beta) monoclonal antibody neutraliz...
13301甲第4507号博士(医学)金沢大学博士論文本文Full 以下に掲載:Clinical Immunology 169 pp.8-13 2016. Elsevier. 共著者:Natsumi I...
OBJECTIVES: Juvenile idiopathic arthritis (JIA) is a heterogeneous group of conditions unified by th...
BACKGROUND: Canakinumab is a human anti-interleukin-1β (IL-1β) monoclonal antibody neutralizing IL-1...
BACKGROUND: Canakinumab is a human anti-interleukin-1β (IL-1β) monoclonal antibody neutralizing IL-1...
Background: Canakinumab is a human anti-interleukin-1β (IL-1β) monoclonal antibody neutralizing IL-1...
Background: Canakinumab is a human anti-interleukin-1β (IL-1β) monoclonal antibody neutralizing IL-1...
Background: Canakinumab is a human anti-interleukin-1\u3b2 (IL-1\u3b2) monoclonal antibody neutraliz...
Background: Canakinumab is a human anti-interleukin-1β (IL-1β) monoclonal antibody neutralizing IL-1...